Biologics & Biosimilars: Impact of Amgen and Hot Topics in Biosimilar Litigation

Join NYIPLA for this year’s Biologics & Biosimilars in-person program on Wednesday, February 7th at Kramer Levin. The Supreme Court’s enablement decision in Amgen v. Sanofi is one of the most impactful patent decisions of this century and will shape biologics litigation for decades to come. It also resolves the divide in the biopharma on what enablement requires and how to promote innovation. In this installment of NYIPLA’s Biologics & Biosimilars program, we will discuss the impact of Amgen on biologics and biosimilar litigation. The program will also cover hot topics in biosimilar litigation, including the outsized role of the PTAB in biosimilar disputes, the continued importance of manufacturing patents, parallel foreign litigation, and more. 

Attendees will be earning up to 1.5 CLE Credits. 

Speakers:

Larry Coury, Vice President, Associate General Counsel, Regeneron 

Mira Mulvaney, Associate VP - Assistant General Patent Counsel, IP Litigation, Eli Lilly and Company

Jen Reda, Assistant General Counsel, Johnson & Johnson

Moderator:

Irena Royzman, Partner, Head of Life Sciences, Kramer Levin Naftalis & Frankel LLP

Materials | Speaker Bios | CLE Evaluation Form

The New York Intellectual Property Law Association extends its gratitude to the sponsor of this event, Kramer Levin Naftalis & Frankel LLP.